Terms: = Lung cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
227 results:
1. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
[TBL] [Abstract] [Full Text] [Related]
2. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
[TBL] [Abstract] [Full Text] [Related]
3. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract] [Full Text] [Related]
4. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
5. Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Tan J; Xue Q; Hu X; Yang J
J Transl Med; 2024 Jan; 22(1):95. PubMed ID: 38263193
[TBL] [Abstract] [Full Text] [Related]
6. The integration of multi-omics analysis and machine learning for the identification of prognostic assessment and immunotherapy efficacy through aging-associated genes in lung cancer.
Lu W; Zhou Y; Zhao R; Liu Q; Yang W; Zhu T
Aging (Albany NY); 2024 Jan; 16(2):1860-1878. PubMed ID: 38261733
[TBL] [Abstract] [Full Text] [Related]
7. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
8. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic and immunological role of adaptor related protein complex 3 subunit mu2 in colon cancer.
Jin Q; Feng J; Yan Y; Kuang Y
Sci Rep; 2024 Jan; 14(1):483. PubMed ID: 38177168
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of immunogenic cell death regulators predicts survival and immunotherapy response in lung adenocarcinoma.
Zhou D; Cui Y; Zhu M; Lin Y; Guo J; Li Y; Zhang J; Wu Z; Guo J; Chen Y; Liang W; Lin W; Lei K; Zhao T; You Q
Life Sci; 2024 Feb; 338():122396. PubMed ID: 38171413
[TBL] [Abstract] [Full Text] [Related]
11. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/ctla-4 Bi-specific antibody): a case report.
Wang X; Yang K; Yang Y; Wang X; Yuan K
Anticancer Drugs; 2024 Mar; 35(3):288-291. PubMed ID: 37982205
[TBL] [Abstract] [Full Text] [Related]
13. Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction.
Zuo B; Wang L; Li X; Li X; Wang J; Xiong Y; Lei J; Zhang X; Chen Y; Liu Q; Jiao J; Sui M; Fan J; Wu N; Song Z; Li G
Aging (Albany NY); 2023 Nov; 15(21):12451-12475. PubMed ID: 37955668
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical pathological characteristics analysis of ocular adnexal follicular lymphoma].
Li J; Wang YC; Lin JY
Zhonghua Yan Ke Za Zhi; 2023 Nov; 59(11):930-936. PubMed ID: 37936361
[No Abstract] [Full Text] [Related]
15. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.
Ding P; Liu P; Meng L; Zhao Q
Eur J Med Res; 2023 Nov; 28(1):492. PubMed ID: 37936161
[TBL] [Abstract] [Full Text] [Related]
16. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract] [Full Text] [Related]
17. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic.
Rios-Hoyo A; Arriola E
Front Immunol; 2023; 14():1221097. PubMed ID: 37876939
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma.
Weng J; Chen J
Medicine (Baltimore); 2023 Oct; 102(41):e35579. PubMed ID: 37832118
[TBL] [Abstract] [Full Text] [Related]
19. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
[No Abstract] [Full Text] [Related]
20. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.
Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B
Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383
[No Abstract] [Full Text] [Related]
[Next]
